Placebo and nocebo in analgesia - psychiatric aspects
Abstract
The paper presents the placebo and nocebo effects that occur in analgesia with a review of way how to recognize them in clinical practice and with the presentation of some psychological and psychiatric elements of the placebo and nocebo effects in clinical practice. The definition of placebo in analgesia implies the reduction of pain due to the use of an inert substance with the information that the substance effectively relieves pain. For now, the mechanism of action of placebo is not completely clear, even in analgesia, but based on numerous studies and extensive clinical experience, it is assumed that there are certain psychological and psychiatric factors that are associated with the placebo effect. On the other hand, the nocebo effect represents the ability of negative beliefs and expectations that cause harm/a negative effect in the body. Thus, nocebo represents the effect of negative expectations from treatment. Unfortunately, there was no research that would indicate the psychological / psychiatric mechanisms of the nocebo effect i clinical practice. Overall, based on extensive experience and based on a number of studies that have been done, it can be concluded that both placebo and nocebo meet in everyday medical practice. How intense it will be depends on many factors. That is why it is important to properly recognize and control them when working with patients. Further research may have profound implications for understanding these phenomena.
References
1 Benedetti F. Mechanisms of placebo and placebo-related effects across diseases and treatments. Ann. Rev. Pharmacol. Toxicol. 2008; 48(33):60.
2 Bajcar EA, Wiercioch-Kuzianik K, Farley D, Adamczyk WM, Buglewicz E, Bąbel P. One of us or one of them? The effects of the model's and observer's characteristics on placebo analgesia induced by observational learning. PLoS One. 2020 Dec 16;15(12):e0243996.
3 Bąbel P. Operant conditioning as a new mechanism of placebo effects. Eur J Pain. 2020; 24(5):902-908.
4 Slomski A. “Important Conversations” Are Needed to Explain the Nocebo Effect. JAMA. 2021; 325(8):707–9.
5 Hahn, R.A., 2000. The nocebo phenomenon: scope and foundations. In: Harrington, A. (Ed.), The Placebo Effect—An Interdisciplinary Exploration. Harvard University Press, pp. 56–76
7 Vambheim SM, Flaten MA. A systematic review of sex differences in the placebo and the nocebo effect. J Pain Res 2017; 10:1831-9.
8 Amanzio M, Palermo S, Skyt I, Vase L. Lessons Learned From Nocebo Effects in Clinical Trials for Pain Conditions and Neurodegenerative Disorders. J Clin Psychopharmacol 2016; 36(5):475-82.
9 Jakovljevic M. The placebo-nocebo response: controversies and challenges from clinical and research perspective. Eur Neuropsychopharmacol. 2014; 24(3):333-41.
10 Kravvariti E, Kitas GD, Sfikakis PP. The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice. Mediterr J Rheumatol. 2019 May 31;30(Suppl 1):63-68.